Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

CytomX Therapeutics, Inc. - Common Stock (NQ:CTMX)

2.030 +0.030 (+1.50%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about CytomX Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
This CytomX Therapeutics Analyst Turns Bullish; Here Are Top 4 Upgrades For Thursday
Via Benzinga
CytomX Stock Hits 2-Month High After Upbeat Q1 Earnings, Promising Early Data For Cancer Drug
The company shared Phase 1 trial results for CX-2051, an antibody-drug conjugate for advanced colorectal cancer, with 28% of patients achieving confirmed partial responses. 
Via Stocktwits
Top movers analysis one hour before the close of the markets on 2025-05-12: top gainers and losers in today's session.
Curious to know what's happening on the US markets one hour before the close of the markets on Monday? Join us as we explore the top gainers and losers in today's session. 
Via Chartmill
Monday's session: most active stocks
These stocks are making the most noise in today's session. Stay tuned for the latest updates! 
Via Chartmill
Earnings Scheduled For May 12, 2025
Via Benzinga
Exploring CytomX Therapeutics's Earnings Expectations
Via Benzinga
(CTMX) - Analyzing CytomX Therapeutics's Short Interest
Via Benzinga
Which stocks are moving on Monday?
Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements. 
Via Chartmill
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
These stocks are gapping in today's session
In today's session, there are notable price gaps in the US markets on Monday. Take a closer look at the stocks that are gap up and gap down. 
Via Chartmill
Nano-Cap CytomX Therapeutics Stock Surges On Heels Of Cancer Data Report
CytomX reported early Phase 1 data for CX-2051 in advanced colorectal cancer, with a 94% disease control rate. 
Via Benzinga
Top movers in Monday's pre-market session
Wondering what's happening in Monday's pre-market session? Find an overview in this article. 
Via Chartmill
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Wondering what's happening in today's pre-market session?
Let's have a look at what is happening on the US markets before the opening bell on Friday. Below you can find the top gainers and losers in today's pre-market session. 
Via Chartmill
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
These stocks are gapping in today's session
The market is buzzing with gapping stocks on Monday. Let's uncover which stocks are experiencing notable gaps during today's session. 
Via Chartmill
Curious about the stocks that are showing activity after the closing bell on Monday?
The US market regular session of Monday is over, let's have a look at the top gainers and losers in the after hours session today. 
Via Chartmill
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Which stocks have an unusual volume on Monday?
Which stocks have an unusual volume on Monday? 
Via Chartmill
Friday's pre-market session: top gainers and losers
As we await the opening of the US market on Friday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment. 
Via Chartmill
Why Gap Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Earnings Scheduled For March 6, 2025
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
CTMX Stock Earnings: CytomX Therapeutics Beats EPS, Beats Revenue for Q2 2024
CTMX stock results show that CytomX Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Buy Alert: 3 Penny Stocks That Will Explode in 2024
Investors should consider these three penny stocks to buy before their success makes them more expensive to gain from. 
Via InvestorPlace
No Memes, Ma’am! Try a Sensible Biotech Bet With CytomX Therapeutics Stock.
It's time to take CytomX Therapeutics stock seriously as CytomX Therapeutics forges a crucial partnership with a pharmaceutical powerhouse. 
Via InvestorPlace
Analysts' Varied Perspectives On CytomX's CX-904 Cancer Study: Safety Profile But Caution in Pancreatic Cancer
Initial data from CytomX Therapeutics' CX-904 Phase 1a study shows safety and anti-cancer activity in heavily pretreated patients with advanced metastatic solid tumors. Reductions observed, especially... 
Via Benzinga
Gold Moves Higher; Roblox Issues Weak Outlook
Via Benzinga
Why Duolingo Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
SOUN Stock Alert: SoundHound AI Announces New Partnership With Perplexity
SoundHound AI stock is slipping on Thursday as SOUN investors appear unimpressed by a new LLM collaboration with Perplexity. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.